Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Country
- 🇨🇳China
- Ownership
- Joint Venture, Subsidiary
- Established
- 1997-04-16
- Employees
- -
- Market Cap
- -
- Website
- http://www.cttq.com
A Study of AL2846 Versus Zoledronic Acid in Subjects With Advanced Non-Small Cell Lung Cancer With Bone Metastasis
- Conditions
- Interventions
- First Posted Date
- 2020-03-30
- Last Posted Date
- 2020-10-12
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT04325776
- Locations
- 🇨🇳
Anhui Chest Hospital, Hefei, Anhui, China
🇨🇳Quzhou People's Hospital, Quzhou, Zhejiang, China
🇨🇳China-Japan Union Hospital Of Jilin University, Changchun, Jilin, China
A Study of TQ05105 Tablets in Subjects With Hemophagocytic Lymphohistiocytosis（HLH）
- First Posted Date
- 2020-03-30
- Last Posted Date
- 2020-09-10
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT04326348
- Locations
- 🇨🇳
Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China
A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2020-03-30
- Last Posted Date
- 2022-03-31
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 315
- Registration Number
- NCT04325763
- Locations
- 🇨🇳
Anhui Chest Hospital, Hefei, Anhui, China
🇨🇳Peking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳Yuebei People's Hospital, Shaoguan, Guangdong, China
A Study of TQ-B3525 in the Treatment of Relapsed / Refractory Follicular Lymphoma (FL)
- First Posted Date
- 2020-03-27
- Last Posted Date
- 2020-07-01
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 80
- Registration Number
- NCT04324879
- Locations
- 🇨🇳
Fifth Medical Center of General Hospital of Chinese People's Liberation Army, Beijing, Beijing, China
🇨🇳The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
🇨🇳Henan Provincial People's Hospital, Zhengzhou, Henan, China
A Study of TQB2450 Injection Combined With Stereotactic Body Radiation Therapy (SBRT) in Subjects With Advanced Oligometastatic Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-03-13
- Last Posted Date
- 2020-03-13
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 59
- Registration Number
- NCT04306926
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Peking University Third Hospital, Beijing, Beijing, China
🇨🇳Tianjin Medical University Cancer institute and Hospital, Tianjin, Tianjin, China
A Study of TQ-B3101 in Subjects With Relapsed or Refractory Anaplastic Large Cell Lymphoma (ALCL)
- Conditions
- Interventions
- First Posted Date
- 2020-03-13
- Last Posted Date
- 2020-03-13
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT04306887
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
A Study of Anlotinib Combined With AK105 Injection in Subjects With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Advanced Solid Tumor
- First Posted Date
- 2020-03-02
- Last Posted Date
- 2020-03-02
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 138
- Registration Number
- NCT04291248
- Locations
- 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China
🇨🇳The Second Affiliated Hospital of The PLA Air Force Medical University, Xi'an, Shanxi, China
🇨🇳Jiangsu Cancer Hospital, Nanjing, Jiangsu, China
A Study of TQA3526 in the Treatment of Primary Biliary Cirrhosis (PBC)
- First Posted Date
- 2020-02-20
- Last Posted Date
- 2020-02-20
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 130
- Registration Number
- NCT04278820
- Locations
- 🇨🇳
The first hospital of Jilin University, Changchun, Jilin, China
A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3602 Capsule
- First Posted Date
- 2020-02-19
- Last Posted Date
- 2020-06-17
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT04275583
- Locations
- 🇨🇳
West China hospital, Sichuan University, Chengdu, Sichuan, China
A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3303 Tablets
- First Posted Date
- 2020-02-19
- Last Posted Date
- 2020-02-19
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT04275050
- Locations
- 🇨🇳
Chinese Academy of Medical Sciencesand Peking Union Medical College, Beijing, Beijing, China